Ustekinumab biosimilar (BioFactura)

乌司奴单抗生物类似药（BioFactura）

Report date: 2025/03/13 20:00:06

Base Information

Drug NameUstekinumab biosimilar (BioFactura)

Drug Alias NameAnti-IL-12/23p40 monoclonal antibody优特克诺Anti-interleukin-12 p40 monoclonal antibody人源抗白介素12单克隆抗体(CNTO 1275)注射剂Ustekinumabum +[10]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar

Mechanisms of ActionInterleukin-12 inhibitorsInterleukin-23 inhibitors

TargetsInterleukin-12Interleukin-23

Therapy Area/IndicationsPsoriasis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNew ZealandAustralia

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsPsoriasis

Inactive IndicationsN/A

ATC CodeN/A